AVBP Live signaler | Maksimer profitt med Getagraph.com

KJøP 121058 min ago

@ $21.16

Utstedt: 14 feb 2024 @ 21:35

Avkastning: -17.96%

Forrige signal: feb 13 - 19:28

Forrige signal: Selg

Avkastning: -2.49 %

Live Chart Being Loaded With Signals

Commentary (8 mai 2024 @ 22:00):

Stats
Dagens volum	40 125.00
Gjennomsnittsvolum	182 196
Markedsverdi	581.45M
Neste inntjeningsdato	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.186 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	555 555	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	313 076	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	3 616 041	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	4 761 903	Series B Preferred Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	55 000 000	Series A Preferred Stock

INSIDER POWER
-74.77
Last 24 transactions
Buy: 9 226 636 \| Sell: 63 909 387

Volum Korrelasjon

Lang: 0.42 (neutral)

Kort: 0.36 (neutral)

Signal:(50.695) Neutral

ArriVent BioPharma, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ArriVent BioPharma, Inc. Korrelasjon - Valuta/Råvare

0.04
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.35
( neutral )

-0.29
( neutral )

0.18
( neutral )

Financial Reports:

No articles found.

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.